Novartis news

Novartis drug Tasigna® meets primary endpoint in pivotal trial against Glivec® as first-line treatment in chronic myeloid leukemia patients

Novartis receives Complete Response letter from FDA for QAB149, an investigational bronchodilator for COPD

Leading Dengue and TB scientists discuss new clinical research approaches and models of excellence for clinical research and trials in endemic regions

Novartis enters into agreement for exclusive US and Canadian rights to Fanapt(TM), an FDA-approved oral therapy for schizophrenia

Novartis gains exclusive worldwide rights to PTK 0796, in Phase III study as potential first-in-class IV and oral broad-spectrum antibiotic

Novartis completes shipment of US supply of Fluvirin® seasonal influenza vaccine

Sandoz launches somatropin, the first-ever Japanese biosimilar, increasing access to key medicines in second largest global market

Two-year Phase III study shows Novartis oral MS therapy FTY720 significantly reduces relapses and disability progression

Novartis bronchodilator QAB149 recommended for approval in European Union to treat patients with chronic obstructive pulmonary disease

Novartis A(H1N1) Pandemic Influenza vaccine Focetria® receives positive opinion from CHMP